
- Pharmaceutical Technology-05-02-2019
- Volume 43
- Issue 5
New Kit Identifies Endonuclease Impurities
The EndonucleaseGTP ELISA Kit from Cygnus Technologies detects and quantitates residual endonuclease impurities in recombinant vaccines and viral vectors used for gene therapy.
The EndonucleaseGTP ELISA Kit from Cygnus Technologies detects and quantitates residual endonuclease impurities in recombinant vaccines and viral vectors used for gene therapy. With a detection limit of ~0.06 ng/mL, the kit is three times more sensitive than the only other commercially available assay for detection and quantitation of these endonuclease impurities, according to the company. The kit also contains all the necessary, ready-to-use reagents for 96 analyses in microplate format, including a set of calibrated endonuclease standards. The assay can be easily integrated into desired workflow points-from process development to quality control to lot release testing.
Articles in this issue
almost 7 years ago
Closed Systems for Aseptic Fill and Finishalmost 7 years ago
Contract Packaging Growsalmost 7 years ago
New Pneumatic Pressesalmost 7 years ago
New Size for AODD Pumpalmost 7 years ago
1000-Gallon Pivoting Triple Shaft Mixeralmost 7 years ago
Bioprocessing Facilities and FDA Inspection Problemsalmost 7 years ago
FDA Faces Challenges After Gottliebalmost 7 years ago
The Auditor Vs. Inspector Issuealmost 7 years ago
Avoiding Excipient Variabilityalmost 7 years ago
Working for the Greater GoodNewsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

